Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Conditions:   Castration Levels of Testosterone;   Hormone-Resistant Prostate Cancer;   Microsatellite Instability Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis Sponsors:   University of Washington;   National Cancer Institute (NCI) Not yet recruiting - verified November 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials